SavedAdd your journal

Journals / Düzce Tıp Fakültesi Dergisi / 2013 / Cilt: 15 - Sayı: 3

The Comparison of Effectiveness of Teriparatide and Alendronate Sodium in Postmenopausal Osteoporosis Treatment

Postmenopozal Osteoporoz Tedavisinde Teriparatid ve Alendronat Sodyumun Etkinliğinin Karşılaştırılması

Ramazan BÜYÜKKAYA
Ertuğrul KAYA
Ali Erdem BAKİ
Yusuf AYDIN
Esra ÇELEBİ
Safinaz ATAOĞLU
Mustafa ÖZŞAHİN
Pages
30–33
Publication Date
2013-12-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

There was a statistically difference onlomber vertebra bone mineral density results of patients who were treated with teriparatide(p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: To evaluate teriparatide and alendronate sodium on bone mineral density ofpostmenopausal women.Materials and methods: Thirty-three postmenopausal women who had been treated withteriparatide and alendronate sodium were evaluated, retrospectively.
📊
Key Findings & Data:There wasn’t a statistically difference between pretreatment andposttreatment results in both groups, either (p>0,05).
💡
Conclusion & Impact:There was a statistically difference onlomber vertebra bone mineral density results of patients who were treated with teriparatide(p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Postmenopozal osteoporoz · teriparatid · alendronat

Abstract

Aim: To evaluate teriparatide and alendronate sodium on bone mineral density ofpostmenopausal women.Materials and methods: Thirty-three postmenopausal women who had been treated withteriparatide and alendronate sodium were evaluated, retrospectively. Patients with a secondaryosteoporosis cause were excluded from the study. Pretreatment and one year after regulartreatment bone mineral density results of lomber vertebra and femur were compared.Results: There wasn’t any statistically difference in femur bone mineral density results betweeneach treatment group. There wasn’t a statistically difference between pretreatment andposttreatment results in both groups, either (p>0,05). There was a statistically difference onlomber vertebra bone mineral density results of patients who were treated with teriparatide(p

Özet

Amaç: Bu çalışmanın amacı, postmenopozal osteoporozlu kadınlarda teriparatid ve alendronatsodyum tedavisinin kemik mineral yoğunluğu (KMY) üzerine etkisini araştırmak, ayrıca ikitedavinin etkinliğini karşılaştırmaktır.Gereç ve Yöntem: Teriparatid ve alendronat sodyum tedavisi almış toplam 33 postmenopozalkadın hasta retrospektif olarak değerlendirildi. Sekonder osteoporoza neden olan patolojileresahip hastalar çalışma dışı bırakıldı. Tedavi öncesi ve 1 yıl düzenli tedavi alan hastaların lombervertebra ve femur KMY ölçümleri karşılaştırıldı.Bulgular: Femur KMY ölçümünde grupların kendi içinde; tedavi sonrası öncesiylekıyaslandığında verilerde istatistiksel olarak anlamlı olmayan iyileşme saptandı (p>0,05).Lomber vertebra KMY ölçümünde teriparatid grubunda istatistiksel olarak anlamlı iyileşmesaptandı (p

🔖

Cite This Article

BÜYÜKKAYA, R., KAYA, E., BAKİ, A. E., AYDIN, Y., ÇELEBİ, E., ATAOĞLU, S., ÖZŞAHİN, M. (2013). The Comparison of Effectiveness of Teriparatide and Alendronate Sodium in Postmenopausal Osteoporosis Treatment. Düzce Tıp Fakültesi Dergisi, Cilt: 15 - Sayı: 3, 30–33. https://ajindex.com/articles/420563

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Conference report (no authors listed). Consensus development conference: prophylaxis and treatment of osteoporosis. Am J Med 1991;90:107-10. Akyüz G. Osteoporozun Sosyal ve Ekonomik Boyutu. T Klin J PM & R 2002;2:96-8.
  2. Gabriel SE, Tosteson AN, Leibson CL, Crowson CS, Pond GR, Hammond CS, et al. Direct medical costs attributable to osteoporotic fractures. Osteoporos Int. 2002;13:323-30.
  3. Watts NB, Diab DL. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 2010;95:1555-65.
  4. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434 Gürer G, Şendur ÖF, Bozbaş GT, Taştaban E. Postmenopozal Osteoporozda Kalsitonin ve Alendronat Tedavilerinin 2 Yıllık Sonuçları. Osteoporoz Dünyasından 2006;12:5-8.
  5. Akyol Y, Tander B, Alayli G, Durmuş D, Bek Y, Cantürk F. Osteoporoz Tedavisinde Alendronat ve Risedronatın Etkinliklerinin Karşılaştırılması. Türk Fiz Tıp Rehab Derg;52:110-4.
  6. Gürer G, Şendur ÖF, Ay C, Erkek A, Odabaşı BB. Postmenopozal Osteoporoz Tedavisinde Raloksifen ve Alendronatın Etkinliklerinin Karşılaştırılması. Osteoporoz Dünyasından 2006;12:12-4.
  7. Kaya K, Delialioğlu SÜ, Özel S, Çulha C, Kurt E, Özgönül S. Postmenopozal Osteoporoz Tedavisinde Stronsiyum Ranelat Karşılaştırılması. Osteoporoz Dünyasından 2009;15:70-4.
  8. Sodyumun Etkinliğinin Heaney RP, Weaver CM. Calcium and vitamin D. Endocrinol Metab Clin North Am 2003;32:181-94.
  9. Sahin M, Demirag NG. Osteoporoz: Tanı ve Tedavide Yenilikler. TOTBİD Dergisi 2004;3(1-2):1-10.
  10. Akarırmak Ü, Ozkul İ. Osteoporoz tedavisinde paratiroid hormon. Osteoporoz Dünyasından 2002;8:42-8.
  11. Langdahl BL, Rajzbaum G, Jakob F, Karras D, Ljunggren O, Lems WF, et al. Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS). Calcif Tissue Int.;85:484-93.
  12. Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res. 2003;18:9-17.
  13. Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, et al. Teriparatide or alendronate in glucocorticoid- induced osteoporosis. N Engl J Med. 2007;357:2028-39.
  14. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM. The effects of parathyroid hor